Search Results
Your search for ,twO matches 12461 pages
Showing 851 - 900Advanced Biliary Tract Cancers: Bevacizumab/Erlotinib Maintenance vs Active Surveillance
In an Indian phase II trial (BEER BTC) reported in the Journal of Clinical Oncology, Ramaswamy et al found that maintenance therapy with bevacizumab/erlotinib improved progression-free survival vs active surveillance in patients with advanced biliary tract cancers who had at least stable disease...
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the...
Can Mindful Breathing Reduce the Intensity of Cancer-Related Pain?
Twenty minutes of mindful breathing, which focuses a person’s attention on their breath, seems to rapidly reduce the intensity and unpleasantness of cancer pain and relieve the associated anxiety, suggest findings from a small comparative study published by Tan et al in BMJ Supportive &...
Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the...
An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate
At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered...
LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer
A subgroup analysis of data from the LIBRETTO-431 trial (ClinicalTrials.gov identifier NCT04194944) showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in East Asian patients diagnosed with RET fusion–positive...
New Modeling Data Show Effective Detection and Health-Care Savings Associated With the Multitarget Stool DNA Test
New modeling data have been released that describe the projected impact of the first and only multitarget stool DNA test (marketed as Cologuard) on patients, health-care professionals, and the U.S. health-care system since its U.S. Food and Drug Administration (FDA) approval 10 years ago. About the ...
Gift of Truth: Reflections on a Father’s Cancer Journey
It was a hot and humid Tuesday in July, and I distinctly remember being grateful for the air conditioning in the pastel-shaded waiting room of the oncology outpatient clinic. My father sat silently beside me. We knew this room well, as we did the doctor we had arrived to see. He had been my...
Age Is Just a Number: Treatment Considerations for Endometrial Cancer in Older Women
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
Breast Cancer Index Confirmed as Prognostic in a SOFT Trial–Derived Population
A prospective-retrospective translational study reported in JAMA Oncology by Ruth M. O’Regan, MD, and colleagues confirmed the prognostic value of the Breast Cancer Index (BCI) in a Suppression of Ovarian Function Trial (SOFT) trial–derived population of premenopausal women with early-stage,...
What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored by two speakers at the 2024 Pan Pacific Lymphoma Conference, sponsored by the University of...
Mouthwash-Based Test May Help Predict Head and Neck Cancer Recurrence
Researchers have examined whether a mouthwash-based test could detect biomarkers to help physicians predict disease recurrence in patients with head and neck cancer, according to a recent study published by Franzmann et al in JAMA Otolaryngology–Head & Neck Surgery. Background Head and neck...
FDA Approves Axatilimab-csfr for Chronic GVHD
On August 14, the U.S. Food and Drug Administration (FDA) approved axatilimab-csfr (Niktimvo), a colony-stimulating factor–1 receptor–blocking antibody, for the treatment of chronic graft-vs-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric...
Efficacy of ‘Symptom-Triggered Testing’ for Detection of Ovarian Cancer
“Symptom-triggered testing”—prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat—detected early-stage aggressive ovarian cancer in one of four individuals affected, according to an analysis from the ROCkeTS trial published by Kwong et al in the ...
Combination Immunotherapies May Boost T-Cell Responses in Patients With Melanoma
Researchers may have uncovered how combination immunotherapies targeting the immune checkpoints PD-1 and LAG-3 may work together to activate immune responses in patients with melanoma, according to two recent studies published by Cillo et al and Andrews et al in Cell. The findings may shed light on ...
Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?
With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission. “Stopping tyrosine kinase inhibitor therapy is something we get a...
Cancer Cases and Mortality Among Men Predicted to Increase Globally
Investigators have uncovered disparities in the projected rates of future cancer incidence and mortality among men based on age and country’s socioeconomic status, according to a recent study published by Bizuayehu et al in Cancer. Background Prior research has shown that men may face higher rates...
Association of Regular Aspirin Use With Colorectal Cancer Risk According to Lifestyle Factors
In a study reported in JAMA Oncology, Sikavi et al found that regular aspirin use was associated with a reduced risk of colorectal cancer overall and among individuals with less healthy vs more healthy lifestyles. Study Details The prospective cohort study focused on data from 107,655 participants...
Can Neoadjuvant Atezolizumab Set a New Standard for Unresectable Stage III NSCLC?
Immune checkpoint inhibitors, including atezolizumab, have been evaluated in several phase II trials for neoadjuvant therapy in resectable lung cancer, both with and without chemotherapy, such as the LCMC3 trial and CheckMate 816. Ongoing studies, including the IMpower030 trial, are further...
Merkel Cell Carcinoma: Association of ctDNA With Recurrence Risk
In a study reported in the Journal of Clinical Oncology, Akaike et al found that detection of circulating tumor DNA (ctDNA) was associated with an increased risk of recurrence in patients with Merkel cell carcinoma. Study Details In the study, a tumor-informed ctDNA assay was used in 319 patients...
Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III CROWN Trial
In an article in the Journal of Clinical Oncology, corresponding author Benjamin J. Solomon, MBBS, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues provided a long-term analysis of 5-year outcomes from the phase III CROWN trial.1 Median progression-free survival had not been...
FDA Approves Immunotherapy for Relapsed or Refractory CTCL
On August 8, the U.S. Food and Drug Administration (FDA) approved denileukin diftitox-cxdl (Lymphir), a novel immunotherapy for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy. Denileukin diftitox is...
Selpercatinib in East Asian Patients With RET Fusion–Positive NSCLC: LIBRETTO-431
Lung cancer is the leading cause of cancer-related death worldwide, accounting for the highest mortality rates among both men and women. Most lung cancers—between 80% and 85%—are non–small cell lung cancer (NSCLC), and between 1% and 2% of patients are diagnosed with RET-altered NSCLC. The results...
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.1...
Births and Adverse Obstetric Outcomes Among Female Survivors of Adolescent and Young Adult Cancers
In a population-based retrospective cohort study (Teenage and Young Adult Cancer Survivor Study; TYACSS) reported in The Lancet Oncology, Sunguc et al identified risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancers in England and Wales. Study Details The...
Common Blood Tests May Improve Early Cancer Diagnosis
The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...
FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma
On August 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have ...
Ponatinib and Blinatumomab in Newly Diagnosed Ph-Positive ALL
In an updated analysis of a single-center phase II trial reported in the Journal of Clinical Oncology, Hagop Kantarjian, MD, and colleagues found that the simultaneous combination of ponatinib and blinatumomab continued to be associated with good outcomes in newly diagnosed patients with...
Glofitamab Combination Therapy Shows Survival Benefit in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A novel treatment regimen with the bispecific antibody glofitamab has demonstrated improvements in survival outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to data presented at the European Hematology Association (EHA) 2024 Congress.1 The phase III ...
Generation X and Millennials Have Higher Risk for Many Cancers Compared to Older Generations
Even though cancer rates continue to fall in older populations, the disease is becoming ever more common among younger age groups. A recent analysis of data from 13 cancer registries in the United States published by Rosenberg et al in JAMA Network Open found that those born between 1965 and 1980...
In Remembrance of My Friend, Lyn Denny, MD, PhD: I Will Never Forget Her
I first met Lyn Denny, MD, PhD, in Ghana, in 2004, when she became the Secretary Treasurer of AORTIC and brought the organization back to life. We’ve been friends ever since. I equate Lyn’s unwavering dedication to bringing health equity to women in Africa to Nelson Mandela’s fight for social...
Gynecologic Oncologist Lynette Ann Denny, MD, PhD, Dies at Age 66
The global oncology and public health communities are mourning the death of Lynette Ann Denny, MD, PhD, a world-renowned gynecologic oncologist and a leading researcher in the prevention of cervical cancer in low-resource settings. Dr. Denny died on June 9, 2024, in Cape Town, South Africa, of...
PIK3CA-Mutated Metastatic Breast Cancer
This is Part 2 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...
Advanced NSCLC: Association of Intratumoral Escherichia With Overall Survival
In a study reported in the Journal of Clinical Oncology, Arielle Elkrief, MD, and colleagues found that detection of intratumoral Escherichia was associated with improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving single-agent immune checkpoint inhibitor ...
Fecal Microbiota Transplant May Help Patients With Gastrointestinal Cancers Overcome Immunotherapy Resistance
Fecal microbiota transplants may improve the effectiveness of immunotherapy in patients with gastrointestinal cancers, according to a recent study published by Kim et al in Cell Host & Microbe. Background Although immune checkpoint inhibitors have revolutionized cancer treatment, many patients...
MRD-Negative ALL: Addition of Blinatumomab to Consolidation Chemotherapy
In the phase III ECOG-ACRIN E1910 trial reported in The New England Journal of Medicine, Mark R. Litzow, MD, and colleagues found that the addition of blinatumomab to consolidation chemotherapy improved overall survival among adult patients with BCR-ABL fusion–negative B-cell precursor acute...
Risk of Breast Cancer May Be Lower Within First 10 Years Following Ovarian Cancer Diagnosis
Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...
Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer
Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...
Cancer and Fatherhood: A Story of Personal Power in the Face of a Mortal Disease
Iron Dad: A Cancer Survivor’s Story of Discovering Strength, Life, and Love Through Fatherhood by Paul Weigel is an inspiring and deeply moving memoir that transcends the traditional boundaries of parenthood and personal transformation. This story begins with a sense of discontent and a desire for...
Addition of Ibrutinib to Immunochemotherapy and ASCT Improves Survival in Mantle Cell Lymphoma
As reported in The Lancet by Martin Dreyling, MD, PhD, of Ludwig Maximilian University Hospital Munich, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell...
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoadjuvant chemoradiotherapy CROSS regimen. The results were presented during the Plenary Session of...
Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...
Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period., according to a recent study published by Ahmed et al in...
pMMR/MSS Locally Advanced Rectal Cancer: Immunotherapy-Based Total Neoadjuvant Therapy
In a Chinese phase II trial (TORCH) reported in the Journal of Clinical Oncology, Xia et al found that integration of the PD-1 inhibitor toripalimab into total neoadjuvant therapy was associated with good outcomes in patients with mismatch repair–proficient or microsatellite-stable (pMMR/MSS)...
Can Living in a Disadvantaged Area Increase the Risk of Aggressive Prostate Cancer?
Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, new research suggests, which in turn may contribute to higher rates of aggressive prostate cancer in African American men. These findings were published by Boyle et al in JAMA Network Open....
Response-Adapted Radiation Therapy for Orbital Indolent B-Cell Lymphoma
In a single-institution phase II trial reported in JAMA Oncology, Pinnix et al found that response-adapted radiation therapy featuring ultra–low-dose radiation therapy was a successful strategy in patients with indolent B-cell lymphoma of the ocular adnexa. As stated by the investigators:...
New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer
The search for biomarkers of response to immunotherapy is high on the list of cancer-related research efforts. A new classifier in triple-negative breast cancer is showing promise and is currently being validated in the I-SPY2.2 trial, according to Laura van ’t Veer, PhD, Professor of Laboratory...
New Imaging Guidelines for Head and Neck Cancers Published
Researchers have developed new imaging guidelines, representing a major shift in the management of patients with head and neck cancers, according to a study published by Henson et al in The Lancet Oncology. The guidelines may lay the foundation for these patients to be treated with tailored...
LBCL: CD22-Directed CAR T-Cell Therapy After Disease Progression on CD19-Directed CAR T-Cell Therapy
In a single-center phase I trial reported in The Lancet, Frank et al found that CD22-directed chimeric antigen receptor (CAR) T-cell therapy (CAR22) showed activity in patients with large B-cell lymphoma (LBCL) whose disease progressed on CD19-directed CAR T-cell therapy (CAR19). CD22 is a nearly...
Long-Term Survival Possible After Liver Transplant for Colorectal Liver Metastases
In selected patients with unresectable colorectal liver metastases, liver transplantation plus chemotherapy significantly boosted overall survival as compared with chemotherapy alone in the multicenter, European TRANSMET trial, presented at the 2024 ASCO Annual Meeting.1 The combined approach led...
